ClinicalTrials.gg
CompletedNCT01732172URISUpdated Mar 27, 2026

Chronic Inflammatory Condition of the Male Genital Tract

An interventional study of Sperm sample in Urethritis, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
113
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Men following after proven and treated urethritis, looking for signs of chronic genital inflammatory syndrome with oxidative stress.

This group of patients will be compared to a control group with no urethritis and no history of urogenital infection. Monocentric, prospective trial.

Duration of study : one year

Read the detailed description

The presence of leucospermia in an chronic inflammatory genital tract syndrome leads to an oxidative stress and alterations in sperm parameters. Inflammation also affect the glands of the genital tract. This can eventually leads to male infertility, long after the initial infection. But 10% of men who seek treatment for infertility have such a leucospermia, while it is a potentially treatable cause.

Main aim of this study: Search of development of an inflammatory genital tract syndrome in patients with urethritis proven and treated at 6 months after the end of treatment.This group of patients will be compared to a control group with no urethritis and no history of urogenital infection. Monocentric, prospective trial.

Primary endpoint: Seminal elastase value to 6 months after the end of treatment. (500ng/ml or greater)

Secondary objective:

  • Search for a genital inflammation in patients with urethritis proven and treated at 12 months after the end of treatment
  • Search for oxidative stress in patients with urethritis proven and treated at 6 and 12 months after the end of treatment
  • Study of the frequency of relapses infectious and / or passages at the stage of chronic infection after acute urethritis
  • Assessment of the parallel evolution of the quality of sperm in the two groups

Progress of research. Time frame Search :

  • Duration of inclusions: 12 months
  • Duration of patient follow-up: 12 months for control group, 14 months at most for patients taking into account the duration of treatment for urethritis which is 4 to 6 weeks
  • Total duration of the study: 26 months

Patients \& Methods: French monocentric, prospective trial. 300 subjects are planned to be included for 150 subjects in each group

02

Conditions studied

  • Urethritis

Keywords

  • Urethritis
  • Prevalence of a chronic inflammatory male genital tract
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 and over
  • Voluntary and signed

Inclusion criteria specific to the group "patient":

  • Patients with clinical signs of urethritis / or
  • Patients treated for urethritis following the usual protocols in the month before inclusionand / or
  • Patients with positive chlamydial research, or Mycoplasma genitallium or Garderella vaginalis or gonorrhea in the sperm or first urinary stream;

Inclusion criteria specific to the group "control":

- Patients with no urethritis or no history of urogenital infection

Exclusion criteria

Exclusion criteria common to both groups:

  • Subjects not wishing to participate in the study
  • Subjects that have not signed the
  • Those not affiliated to the social security system (or entitled beneficiary)
  • Immunodepressed or have an infection associated with , or
  • Chronic systemic disease

Exclusion criteria specific to the group "patient":

- Patients with no signs of urethritis

Exclusion criteria specific to the group "control":

- Subjects with signs of urethritis

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Patient Group

    Patient with urethritis

    Other: Sperm sample

  • Other
    Control group

    Subjects with no urethritis and no history urogenital infection

    Other: Sperm sample

Interventions

  • OtherSperm sample

    Sperm sample

06

What researchers measure

Primary outcomes

  1. Seminal elastase value

    The dosage of elastase will be do 6 months after the end of treatment.

    Time frame: 6 months after the end of treatment.

Secondary outcomes

  1. Seminal elastase value

    The dosage of elastase will be do 12 months after the end of treatment.

    Time frame: 12 months after the end of treatment.

  2. Presence of markers of oxidative stress

    Presence of markers objectifying the existence of oxidative stress resulting in cellular alterations: Determination of 8-hydroxydeoxyguanosine (8-OHdG) and AOPP (Advanced Oxidation Protein Products)

    Time frame: 6 to 12 months after the end of treatment

  3. Functional impairment of the glands of the reproductive tract

    Presence of biochemical evidence indicating a functional impairment of the glands of the reproductive tract (markers of prostate, seminal vesicles, and epididymis to the seminal biochemistry)

    Time frame: 6 to 12 months after the end of treatment

  4. Signs reflecting the sperm function

    Presence of signs reflecting the sperm function (vitality, mobility, analysis of motion parameters by Computer Assisted Semen Analyzer(CASA))

    Time frame: 6 to 12 months after the end of treatment

07

Study locations

1 site
  • Hospital Cochin
    Paris, 75014, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2012 to primary completion in Feb 2016, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2012
First posted
Nov 22, 2012
StartActual
Dec 10, 2012
Primary completionActual
Feb 29, 2016
CompletionActual
Feb 29, 2016
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01732172
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Nov 22, 2012
Start date
Dec 10, 2012
Primary completion
Feb 29, 2016
Completion
Feb 29, 2016
Last update
Mar 27, 2026

Study contacts

Jean-Philippe WOLF, MD, PhD
principal investigator · Cochin Hospital
Khaled POCATE, MD
principal investigator · Cochin Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion